| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 32 | 2020 | 4638 | 1.710 |
Why?
|
| Gene Expression Profiling | 39 | 2020 | 5159 | 1.700 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 23 | 2017 | 2508 | 1.240 |
Why?
|
| Genomics | 11 | 2021 | 2738 | 1.170 |
Why?
|
| Research Design | 7 | 2018 | 1544 | 1.080 |
Why?
|
| Periodicals as Topic | 4 | 2013 | 338 | 0.900 |
Why?
|
| DNA Methylation | 12 | 2021 | 2669 | 0.870 |
Why?
|
| Blood Proteins | 6 | 2010 | 294 | 0.860 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 11 | 2018 | 208 | 0.840 |
Why?
|
| MicroRNAs | 13 | 2019 | 2947 | 0.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 35 | 2019 | 8873 | 0.720 |
Why?
|
| Protein Array Analysis | 9 | 2014 | 501 | 0.710 |
Why?
|
| Proteomics | 9 | 2019 | 1380 | 0.680 |
Why?
|
| Mass Spectrometry | 4 | 2006 | 702 | 0.640 |
Why?
|
| Urinary Bladder Neoplasms | 13 | 2019 | 2341 | 0.610 |
Why?
|
| RNA, Messenger | 12 | 2017 | 6150 | 0.580 |
Why?
|
| Neoplasms, Glandular and Epithelial | 7 | 2017 | 519 | 0.580 |
Why?
|
| Algorithms | 15 | 2019 | 3890 | 0.540 |
Why?
|
| Cystadenocarcinoma, Serous | 6 | 2020 | 486 | 0.540 |
Why?
|
| Biomarkers, Tumor | 28 | 2019 | 10331 | 0.540 |
Why?
|
| Proteome | 5 | 2007 | 561 | 0.500 |
Why?
|
| Carcinoma | 6 | 2019 | 2578 | 0.460 |
Why?
|
| Research | 2 | 2018 | 415 | 0.440 |
Why?
|
| Neoplasms | 14 | 2019 | 15193 | 0.430 |
Why?
|
| Mutation | 17 | 2019 | 15179 | 0.430 |
Why?
|
| Cell Line, Tumor | 30 | 2020 | 14551 | 0.420 |
Why?
|
| Reproducibility of Results | 17 | 2018 | 6009 | 0.390 |
Why?
|
| Humans | 123 | 2021 | 261506 | 0.390 |
Why?
|
| CA-125 Antigen | 4 | 2019 | 226 | 0.380 |
Why?
|
| Information Dissemination | 1 | 2013 | 272 | 0.360 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3230 | 0.350 |
Why?
|
| Biotechnology | 2 | 2010 | 63 | 0.350 |
Why?
|
| Peptide Mapping | 5 | 2007 | 114 | 0.350 |
Why?
|
| Disclosure | 1 | 2010 | 181 | 0.340 |
Why?
|
| Databases, Protein | 3 | 2009 | 100 | 0.340 |
Why?
|
| Female | 78 | 2021 | 141928 | 0.330 |
Why?
|
| Sequence Analysis, DNA | 5 | 2012 | 2483 | 0.330 |
Why?
|
| Publishing | 1 | 2010 | 220 | 0.320 |
Why?
|
| Phosphoproteins | 2 | 2013 | 1152 | 0.320 |
Why?
|
| Genome, Human | 3 | 2019 | 1869 | 0.310 |
Why?
|
| Breast Neoplasms | 18 | 2018 | 15694 | 0.310 |
Why?
|
| Gene Library | 4 | 2005 | 294 | 0.300 |
Why?
|
| Sequence Analysis, Protein | 4 | 2009 | 81 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2019 | 15862 | 0.290 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2018 | 52 | 0.280 |
Why?
|
| Colonic Neoplasms | 2 | 2012 | 1390 | 0.280 |
Why?
|
| Vitamin D | 3 | 2017 | 261 | 0.280 |
Why?
|
| Rectal Neoplasms | 2 | 2012 | 1202 | 0.270 |
Why?
|
| Myotonic Dystrophy | 3 | 2013 | 151 | 0.270 |
Why?
|
| Biomedical Research | 2 | 2011 | 806 | 0.270 |
Why?
|
| Gene Regulatory Networks | 4 | 2019 | 677 | 0.270 |
Why?
|
| Acetamides | 2 | 2018 | 113 | 0.270 |
Why?
|
| Sensitivity and Specificity | 11 | 2018 | 4971 | 0.260 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 1439 | 0.250 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2017 | 3552 | 0.250 |
Why?
|
| DNA Copy Number Variations | 6 | 2018 | 1516 | 0.250 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 118 | 0.250 |
Why?
|
| Endometrial Neoplasms | 3 | 2021 | 1341 | 0.250 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2021 | 6915 | 0.240 |
Why?
|
| Proteins | 5 | 2017 | 1963 | 0.240 |
Why?
|
| Indoles | 3 | 2015 | 1009 | 0.240 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2016 | 962 | 0.240 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 101 | 0.230 |
Why?
|
| Glioma | 4 | 2010 | 1963 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2017 | 5437 | 0.220 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2019 | 436 | 0.220 |
Why?
|
| Prognosis | 18 | 2021 | 21713 | 0.220 |
Why?
|
| Myotonic Disorders | 2 | 2013 | 13 | 0.220 |
Why?
|
| Signal Transduction | 12 | 2021 | 11965 | 0.220 |
Why?
|
| Nerve Tissue Proteins | 3 | 2017 | 1491 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 164 | 0.220 |
Why?
|
| Mice, Nude | 11 | 2021 | 4307 | 0.220 |
Why?
|
| Software | 7 | 2021 | 1321 | 0.220 |
Why?
|
| Urothelium | 4 | 2019 | 254 | 0.220 |
Why?
|
| RNA, Small Interfering | 6 | 2015 | 2216 | 0.210 |
Why?
|
| Muscular Dystrophies | 2 | 2013 | 51 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2021 | 1546 | 0.210 |
Why?
|
| Cluster Analysis | 6 | 2017 | 1053 | 0.210 |
Why?
|
| Receptors, Prolactin | 2 | 2020 | 27 | 0.210 |
Why?
|
| Transcriptome | 5 | 2017 | 1859 | 0.200 |
Why?
|
| Genetic Variation | 3 | 2014 | 2086 | 0.200 |
Why?
|
| Models, Statistical | 4 | 2007 | 1171 | 0.200 |
Why?
|
| Mutation Rate | 2 | 2012 | 223 | 0.200 |
Why?
|
| Random Allocation | 2 | 2018 | 703 | 0.200 |
Why?
|
| Receptor, Notch3 | 2 | 2018 | 31 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2019 | 2054 | 0.200 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2014 | 161 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 73 | 0.190 |
Why?
|
| Models, Genetic | 2 | 2003 | 1113 | 0.190 |
Why?
|
| Middle Aged | 33 | 2021 | 86204 | 0.190 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 113 | 0.190 |
Why?
|
| 3' Untranslated Regions | 2 | 2019 | 343 | 0.180 |
Why?
|
| Receptors, Notch | 2 | 2014 | 383 | 0.180 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 487 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 3 | 2016 | 3101 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2021 | 185 | 0.180 |
Why?
|
| Genome | 1 | 2013 | 672 | 0.180 |
Why?
|
| Mice | 23 | 2021 | 34495 | 0.180 |
Why?
|
| Cell Proliferation | 14 | 2018 | 7226 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5178 | 0.170 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2019 | 178 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2016 | 1823 | 0.170 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2004 | 542 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 44 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 1547 | 0.170 |
Why?
|
| Transcription Factors | 5 | 2018 | 5270 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 4549 | 0.160 |
Why?
|
| Apoptosis | 11 | 2016 | 7591 | 0.160 |
Why?
|
| Validation Studies as Topic | 1 | 2018 | 43 | 0.160 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 160 | 0.160 |
Why?
|
| Survivorship | 1 | 2018 | 109 | 0.160 |
Why?
|
| Vitamin D Deficiency | 2 | 2017 | 115 | 0.160 |
Why?
|
| Aflatoxins | 1 | 2017 | 13 | 0.160 |
Why?
|
| Azepines | 1 | 2018 | 124 | 0.160 |
Why?
|
| Antineoplastic Agents | 5 | 2015 | 14289 | 0.160 |
Why?
|
| Publications | 1 | 2018 | 54 | 0.160 |
Why?
|
| Ethics, Research | 1 | 2018 | 67 | 0.160 |
Why?
|
| DNA | 4 | 2017 | 2693 | 0.160 |
Why?
|
| Nuclear Proteins | 3 | 2019 | 3343 | 0.150 |
Why?
|
| Aged | 28 | 2019 | 70117 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2019 | 266 | 0.150 |
Why?
|
| Dietary Supplements | 3 | 2017 | 558 | 0.150 |
Why?
|
| Aurora Kinase A | 2 | 2017 | 202 | 0.150 |
Why?
|
| Precision Medicine | 3 | 2015 | 1154 | 0.150 |
Why?
|
| CD24 Antigen | 1 | 2017 | 85 | 0.150 |
Why?
|
| Urethral Neoplasms | 1 | 2017 | 60 | 0.150 |
Why?
|
| Oncostatin M | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cholecalciferol | 1 | 2017 | 46 | 0.150 |
Why?
|
| Animals | 27 | 2021 | 59536 | 0.150 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 101 | 0.150 |
Why?
|
| Urethra | 1 | 2017 | 144 | 0.150 |
Why?
|
| Clonal Evolution | 1 | 2019 | 253 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2232 | 0.140 |
Why?
|
| Zinc | 1 | 2017 | 188 | 0.140 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2016 | 33 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 216 | 0.140 |
Why?
|
| Cell Survival | 7 | 2018 | 3045 | 0.140 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2017 | 155 | 0.140 |
Why?
|
| Epigenesis, Genetic | 4 | 2019 | 1399 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2021 | 1234 | 0.140 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 973 | 0.140 |
Why?
|
| Ovary | 3 | 2016 | 668 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2021 | 1385 | 0.140 |
Why?
|
| Vitamins | 1 | 2017 | 157 | 0.140 |
Why?
|
| Macular Degeneration | 1 | 2017 | 114 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2017 | 986 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2017 | 272 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 275 | 0.140 |
Why?
|
| Lung Neoplasms | 4 | 2013 | 11538 | 0.140 |
Why?
|
| Genes, ras | 1 | 2019 | 667 | 0.140 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2016 | 67 | 0.140 |
Why?
|
| Muscle, Skeletal | 3 | 2013 | 1270 | 0.140 |
Why?
|
| Disease Progression | 5 | 2019 | 6682 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2014 | 3639 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 545 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2017 | 1215 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 315 | 0.130 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 41 | 0.130 |
Why?
|
| Pattern Recognition, Automated | 2 | 2007 | 125 | 0.130 |
Why?
|
| Aspartic Acid | 1 | 2016 | 126 | 0.130 |
Why?
|
| Integrin beta Chains | 1 | 2015 | 34 | 0.130 |
Why?
|
| Acetyltransferases | 1 | 2016 | 143 | 0.130 |
Why?
|
| Anoikis | 1 | 2015 | 63 | 0.130 |
Why?
|
| Obstetric Labor, Premature | 1 | 2015 | 80 | 0.130 |
Why?
|
| Arylsulfotransferase | 1 | 2015 | 18 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 5 | 2019 | 1077 | 0.130 |
Why?
|
| Receptors, Estrogen | 3 | 2018 | 2086 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 7789 | 0.130 |
Why?
|
| Mesoderm | 1 | 2017 | 404 | 0.130 |
Why?
|
| Down-Regulation | 6 | 2016 | 2074 | 0.130 |
Why?
|
| Transfection | 6 | 2021 | 2944 | 0.130 |
Why?
|
| Gene Silencing | 3 | 2015 | 837 | 0.130 |
Why?
|
| Immunohistochemistry | 11 | 2016 | 7548 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 3 | 2017 | 2518 | 0.120 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 3719 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2014 | 33 | 0.120 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2005 | 81 | 0.120 |
Why?
|
| RNA Splicing | 2 | 2013 | 370 | 0.120 |
Why?
|
| Antioxidants | 1 | 2017 | 507 | 0.120 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2014 | 26 | 0.120 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 2045 | 0.120 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2017 | 560 | 0.120 |
Why?
|
| Research Personnel | 2 | 2018 | 156 | 0.120 |
Why?
|
| Cell Movement | 7 | 2017 | 2466 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 2326 | 0.120 |
Why?
|
| Cell Membrane | 1 | 2017 | 850 | 0.120 |
Why?
|
| Doxorubicin | 6 | 2015 | 3005 | 0.120 |
Why?
|
| Gene Expression | 5 | 2019 | 3570 | 0.120 |
Why?
|
| Adult | 24 | 2020 | 77950 | 0.120 |
Why?
|
| Databases, Genetic | 4 | 2019 | 745 | 0.120 |
Why?
|
| Peptide Library | 2 | 2006 | 158 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 65 | 0.120 |
Why?
|
| Stathmin | 1 | 2013 | 30 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2015 | 1217 | 0.110 |
Why?
|
| Complement System Proteins | 1 | 2014 | 139 | 0.110 |
Why?
|
| Phosphates | 1 | 2014 | 187 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 108 | 0.110 |
Why?
|
| Muscle Neoplasms | 1 | 2014 | 109 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 146 | 0.110 |
Why?
|
| Male | 24 | 2019 | 123000 | 0.110 |
Why?
|
| Lactones | 1 | 2013 | 94 | 0.110 |
Why?
|
| Leukemia, Experimental | 1 | 2012 | 78 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.110 |
Why?
|
| Premature Birth | 1 | 2017 | 407 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2012 | 125 | 0.110 |
Why?
|
| DNA, Neoplasm | 5 | 2018 | 1910 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2014 | 358 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2019 | 3154 | 0.100 |
Why?
|
| Gene Dosage | 2 | 2014 | 829 | 0.100 |
Why?
|
| Crk-Associated Substrate Protein | 1 | 2011 | 27 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 3022 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 318 | 0.100 |
Why?
|
| Computational Biology | 5 | 2019 | 1271 | 0.100 |
Why?
|
| Retinoblastoma Protein | 3 | 2008 | 335 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2014 | 1248 | 0.100 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.100 |
Why?
|
| Myotonia Congenita | 1 | 2010 | 6 | 0.100 |
Why?
|
| Alternative Splicing | 3 | 2010 | 584 | 0.100 |
Why?
|
| MADS Domain Proteins | 1 | 2010 | 10 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 735 | 0.100 |
Why?
|
| Colon | 2 | 2005 | 670 | 0.100 |
Why?
|
| Phosphotyrosine | 1 | 2011 | 111 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2017 | 2819 | 0.100 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2010 | 35 | 0.100 |
Why?
|
| Cyclin D2 | 1 | 2010 | 40 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2012 | 1678 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 272 | 0.100 |
Why?
|
| Papillomaviridae | 2 | 2017 | 624 | 0.100 |
Why?
|
| Purines | 1 | 2012 | 273 | 0.100 |
Why?
|
| ErbB Receptors | 2 | 2011 | 2295 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2013 | 478 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2015 | 2796 | 0.090 |
Why?
|
| Calcium | 1 | 2017 | 1537 | 0.090 |
Why?
|
| Cell Cycle | 6 | 2017 | 2084 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 1143 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 5 | 2019 | 3981 | 0.090 |
Why?
|
| Sarcoma | 2 | 2019 | 1725 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 2283 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 2238 | 0.090 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2014 | 475 | 0.090 |
Why?
|
| Genes, p53 | 2 | 2012 | 1090 | 0.090 |
Why?
|
| Cisplatin | 2 | 2014 | 2432 | 0.090 |
Why?
|
| Models, Chemical | 2 | 2007 | 186 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2018 | 9244 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 395 | 0.090 |
Why?
|
| STAT5 Transcription Factor | 1 | 2011 | 214 | 0.090 |
Why?
|
| Myosins | 1 | 2010 | 96 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2018 | 3821 | 0.090 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 67 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 854 | 0.090 |
Why?
|
| Survival Rate | 4 | 2016 | 12221 | 0.090 |
Why?
|
| Epithelial Cells | 2 | 2009 | 1818 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 29902 | 0.090 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 2009 | 36 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 2291 | 0.090 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 116 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2009 | 55 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1443 | 0.090 |
Why?
|
| Culture Media | 1 | 2010 | 319 | 0.090 |
Why?
|
| PPAR gamma | 3 | 2016 | 229 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 941 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 260 | 0.080 |
Why?
|
| RNA, Neoplasm | 2 | 2009 | 771 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2008 | 141 | 0.080 |
Why?
|
| Muscular Atrophy | 1 | 2010 | 105 | 0.080 |
Why?
|
| Papillomavirus Infections | 1 | 2017 | 980 | 0.080 |
Why?
|
| Cyclophosphamide | 4 | 2015 | 3001 | 0.080 |
Why?
|
| Glioblastoma | 2 | 2011 | 1797 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2009 | 1529 | 0.080 |
Why?
|
| Tissue Array Analysis | 3 | 2016 | 760 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2359 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2004 | 2307 | 0.080 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2013 | 509 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6207 | 0.080 |
Why?
|
| Receptor, EphA2 | 1 | 2009 | 132 | 0.080 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2007 | 209 | 0.080 |
Why?
|
| Troponin T | 1 | 2010 | 261 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2011 | 1163 | 0.080 |
Why?
|
| Lasers | 2 | 2010 | 198 | 0.080 |
Why?
|
| CpG Islands | 2 | 2016 | 633 | 0.080 |
Why?
|
| Logistic Models | 3 | 2017 | 3441 | 0.080 |
Why?
|
| RNA Precursors | 1 | 2008 | 137 | 0.080 |
Why?
|
| Body Fluids | 2 | 2005 | 125 | 0.080 |
Why?
|
| Fluorouracil | 3 | 2010 | 1944 | 0.080 |
Why?
|
| Oligonucleotide Probes | 1 | 2007 | 130 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2012 | 1442 | 0.080 |
Why?
|
| Receptor, ErbB-3 | 1 | 2007 | 122 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2008 | 369 | 0.070 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1471 | 0.070 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 13658 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 1265 | 0.070 |
Why?
|
| Base Sequence | 6 | 2010 | 4917 | 0.070 |
Why?
|
| Computer Graphics | 1 | 2006 | 82 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 622 | 0.070 |
Why?
|
| Exome | 1 | 2012 | 1239 | 0.070 |
Why?
|
| Nipples | 2 | 2005 | 132 | 0.070 |
Why?
|
| Paclitaxel | 5 | 2014 | 1996 | 0.070 |
Why?
|
| Calibration | 2 | 2005 | 337 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 2864 | 0.070 |
Why?
|
| Pyridines | 1 | 2013 | 1244 | 0.070 |
Why?
|
| Risk Factors | 3 | 2018 | 17523 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3869 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 3578 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 4298 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2009 | 519 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 292 | 0.070 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 135 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2016 | 1742 | 0.070 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 1258 | 0.070 |
Why?
|
| Biopsy | 2 | 2015 | 3443 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2014 | 2054 | 0.070 |
Why?
|
| Bayes Theorem | 2 | 2007 | 1021 | 0.070 |
Why?
|
| Loss of Heterozygosity | 3 | 2016 | 602 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 927 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 2027 | 0.060 |
Why?
|
| Mathematical Computing | 1 | 2004 | 22 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1037 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2015 | 1546 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2014 | 1823 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2017 | 5395 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 286 | 0.060 |
Why?
|
| Protein Isoforms | 3 | 2013 | 842 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1429 | 0.060 |
Why?
|
| Fallopian Tubes | 1 | 2005 | 119 | 0.060 |
Why?
|
| Organ Specificity | 3 | 2018 | 699 | 0.060 |
Why?
|
| Survival Analysis | 5 | 2016 | 9180 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2005 | 184 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2012 | 2358 | 0.060 |
Why?
|
| Tumor Burden | 3 | 2016 | 1987 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 5319 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 4757 | 0.060 |
Why?
|
| Bias | 1 | 2004 | 205 | 0.060 |
Why?
|
| Discriminant Analysis | 1 | 2003 | 48 | 0.060 |
Why?
|
| Phosphatidylcholines | 2 | 2016 | 144 | 0.060 |
Why?
|
| Multigene Family | 1 | 2005 | 425 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2015 | 3536 | 0.060 |
Why?
|
| Restriction Mapping | 1 | 2003 | 264 | 0.060 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 2138 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 2009 | 3976 | 0.060 |
Why?
|
| Treatment Outcome | 9 | 2019 | 32848 | 0.050 |
Why?
|
| Vinblastine | 2 | 2014 | 453 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 4 | 2014 | 4975 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 10001 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2019 | 1544 | 0.050 |
Why?
|
| Exons | 3 | 2013 | 1328 | 0.050 |
Why?
|
| Phylogeny | 1 | 2005 | 826 | 0.050 |
Why?
|
| Microtubules | 2 | 2013 | 270 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 641 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2330 | 0.050 |
Why?
|
| Microsatellite Repeats | 2 | 2017 | 575 | 0.050 |
Why?
|
| Endometrium | 1 | 2005 | 470 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 2576 | 0.050 |
Why?
|
| Neoplasm Metastasis | 4 | 2014 | 5112 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10035 | 0.050 |
Why?
|
| Cell Growth Processes | 2 | 2014 | 342 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2004 | 494 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2011 | 2450 | 0.050 |
Why?
|
| Information Theory | 1 | 2001 | 9 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2016 | 368 | 0.050 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2001 | 19 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2014 | 886 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 217 | 0.050 |
Why?
|
| Artifacts | 1 | 2004 | 532 | 0.050 |
Why?
|
| Phosphorylation | 3 | 2014 | 4804 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2019 | 3033 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4557 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 1 | 2005 | 701 | 0.050 |
Why?
|
| Peptides | 1 | 2006 | 1479 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 374 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2001 | 225 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2004 | 674 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2013 | 621 | 0.040 |
Why?
|
| Benzylamines | 1 | 2019 | 105 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cell Line | 3 | 2017 | 5114 | 0.040 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 59 | 0.040 |
Why?
|
| Receptors, Androgen | 2 | 2015 | 878 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 905 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2019 | 119 | 0.040 |
Why?
|
| Gene Amplification | 2 | 2008 | 731 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 2489 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 5767 | 0.040 |
Why?
|
| Molecular Sequence Data | 4 | 2007 | 6089 | 0.040 |
Why?
|
| Alleles | 2 | 2017 | 2437 | 0.040 |
Why?
|
| Poisons | 1 | 2017 | 9 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2019 | 271 | 0.040 |
Why?
|
| Professional Practice | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 671 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2011 | 694 | 0.040 |
Why?
|
| Complement Factor H | 1 | 2017 | 33 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 14889 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.040 |
Why?
|
| Nebraska | 1 | 2017 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 4053 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 483 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 87 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 1216 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 2017 | 167 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2017 | 37 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 650 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 130 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2017 | 40 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 314 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 225 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 4892 | 0.040 |
Why?
|
| United Kingdom | 1 | 2017 | 257 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 3260 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2014 | 650 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 310 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 202 | 0.040 |
Why?
|
| Keratin-14 | 1 | 2016 | 24 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.040 |
Why?
|
| Uroplakin II | 1 | 2016 | 15 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 478 | 0.040 |
Why?
|
| Genotype | 2 | 2017 | 4109 | 0.040 |
Why?
|
| Stress Fibers | 1 | 2016 | 15 | 0.040 |
Why?
|
| DNA Primers | 2 | 2009 | 1399 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 2017 | 137 | 0.030 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2016 | 85 | 0.030 |
Why?
|
| South Carolina | 1 | 2015 | 18 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 3890 | 0.030 |
Why?
|
| Focal Adhesions | 1 | 2016 | 45 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2019 | 749 | 0.030 |
Why?
|
| Recurrence | 2 | 2015 | 4758 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 4233 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2016 | 96 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2016 | 79 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 43 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 111 | 0.030 |
Why?
|
| Students | 1 | 2018 | 324 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2016 | 146 | 0.030 |
Why?
|
| COP9 Signalosome Complex | 1 | 2015 | 72 | 0.030 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2017 | 224 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 249 | 0.030 |
Why?
|
| Busulfan | 1 | 2019 | 764 | 0.030 |
Why?
|
| Prenatal Care | 1 | 2017 | 325 | 0.030 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2014 | 10 | 0.030 |
Why?
|
| Chemical Fractionation | 2 | 2005 | 27 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2004 | 44 | 0.030 |
Why?
|
| Sister Chromatid Exchange | 1 | 1994 | 45 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 548 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2015 | 348 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2014 | 85 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 323 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 287 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4744 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 242 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| Dynamins | 1 | 2014 | 74 | 0.030 |
Why?
|
| Vidarabine | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2016 | 338 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 560 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1688 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2014 | 101 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2014 | 62 | 0.030 |
Why?
|
| U937 Cells | 1 | 2014 | 171 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2014 | 126 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2015 | 4078 | 0.030 |
Why?
|
| Pruritus | 1 | 2014 | 87 | 0.030 |
Why?
|
| Complement Activation | 1 | 2014 | 94 | 0.030 |
Why?
|
| Gestational Age | 1 | 2017 | 1069 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1945 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2017 | 576 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2014 | 302 | 0.030 |
Why?
|
| Epithelium | 1 | 2016 | 720 | 0.030 |
Why?
|
| Genomic Imprinting | 1 | 2014 | 194 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 612 | 0.030 |
Why?
|
| Fatty Acid Synthases | 1 | 2013 | 24 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2016 | 434 | 0.030 |
Why?
|
| Pregnancy | 2 | 2017 | 7573 | 0.030 |
Why?
|
| Epirubicin | 1 | 2013 | 157 | 0.030 |
Why?
|
| Chromosomes | 1 | 1994 | 244 | 0.030 |
Why?
|
| Internet | 1 | 2018 | 706 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 2013 | 116 | 0.030 |
Why?
|
| Endocytosis | 1 | 2014 | 225 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 21445 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 289 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2015 | 344 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 3 | 2005 | 5061 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 566 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 333 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 703 | 0.030 |
Why?
|
| Tyrosine | 1 | 2014 | 498 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2013 | 240 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 987 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 68 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 937 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2015 | 575 | 0.030 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 598 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 769 | 0.030 |
Why?
|
| Pericytes | 1 | 2013 | 96 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 4844 | 0.030 |
Why?
|
| Bleomycin | 1 | 2013 | 467 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 503 | 0.030 |
Why?
|
| Morpholines | 1 | 2013 | 289 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2005 | 869 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2013 | 227 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 700 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2011 | 85 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 211 | 0.030 |
Why?
|
| Reference Standards | 2 | 2003 | 339 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 545 | 0.030 |
Why?
|
| Finland | 1 | 2011 | 55 | 0.020 |
Why?
|
| Survivors | 1 | 2017 | 1031 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2013 | 485 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2012 | 217 | 0.020 |
Why?
|
| Epigenomics | 1 | 2012 | 266 | 0.020 |
Why?
|
| MafB Transcription Factor | 1 | 2010 | 12 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2017 | 2588 | 0.020 |
Why?
|
| Quality Control | 2 | 2003 | 457 | 0.020 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2012 | 265 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 252 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4849 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 568 | 0.020 |
Why?
|
| MEF2 Transcription Factors | 1 | 2010 | 47 | 0.020 |
Why?
|
| Biomarkers | 2 | 2015 | 5047 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2011 | 65 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 665 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 1991 | 74 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2012 | 626 | 0.020 |
Why?
|
| Vincristine | 1 | 2015 | 1511 | 0.020 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 1363 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 702 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 999 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2015 | 787 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 519 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 576 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 269 | 0.020 |
Why?
|
| Models, Biological | 2 | 2013 | 3254 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2019 | 1471 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1313 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1450 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2004 | 785 | 0.020 |
Why?
|
| Nogo Proteins | 1 | 2009 | 11 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2010 | 104 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2011 | 242 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2015 | 1620 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 852 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1493 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 342 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 2009 | 82 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Myelin Proteins | 1 | 2009 | 90 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2009 | 69 | 0.020 |
Why?
|
| Alu Elements | 1 | 2009 | 88 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 726 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 7222 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 2422 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 534 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2008 | 189 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2008 | 105 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2016 | 1616 | 0.020 |
Why?
|
| Receptor, ErbB-4 | 1 | 2007 | 23 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2013 | 554 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 1869 | 0.020 |
Why?
|
| Sirolimus | 1 | 2012 | 814 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1048 | 0.020 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2007 | 28 | 0.020 |
Why?
|
| Taxoids | 1 | 2011 | 967 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2009 | 286 | 0.020 |
Why?
|
| Affinity Labels | 1 | 2007 | 28 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 1519 | 0.020 |
Why?
|
| Metaplasia | 1 | 2009 | 383 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2016 | 2022 | 0.020 |
Why?
|
| NF-kappa B | 2 | 2004 | 1549 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1301 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 4314 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 2265 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 666 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2009 | 521 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2008 | 182 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2006 | 63 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 5673 | 0.020 |
Why?
|
| Phenotype | 2 | 2011 | 6295 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 691 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 6311 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 4938 | 0.020 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2005 | 34 | 0.020 |
Why?
|
| Complex Mixtures | 1 | 2005 | 3 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2006 | 392 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 844 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2008 | 575 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2004 | 39 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2005 | 45 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1245 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 37905 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2004 | 60 | 0.020 |
Why?
|
| ras Proteins | 1 | 2009 | 770 | 0.020 |
Why?
|
| Response Elements | 1 | 2005 | 193 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 31252 | 0.020 |
Why?
|
| Cystectomy | 1 | 2008 | 623 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 117 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5539 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2173 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 1487 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 203 | 0.010 |
Why?
|
| Clone Cells | 1 | 2005 | 555 | 0.010 |
Why?
|
| Suction | 1 | 2003 | 104 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 212 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 995 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2007 | 388 | 0.010 |
Why?
|
| Child | 2 | 2015 | 29154 | 0.010 |
Why?
|
| Quality of Life | 1 | 2017 | 4532 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Mathematics | 2 | 1994 | 136 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8223 | 0.010 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 323 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2007 | 1732 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1331 | 0.010 |
Why?
|
| Pancreas | 1 | 2006 | 718 | 0.010 |
Why?
|
| Radioactivity | 1 | 2001 | 1 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2005 | 974 | 0.010 |
Why?
|
| GTP Phosphohydrolases | 1 | 2004 | 336 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 1450 | 0.010 |
Why?
|
| Biometry | 1 | 2003 | 241 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2004 | 267 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 668 | 0.010 |
Why?
|
| Fluorescence | 1 | 2001 | 195 | 0.010 |
Why?
|
| Uterus | 1 | 2006 | 678 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 482 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2005 | 1064 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 554 | 0.010 |
Why?
|
| Estrogens | 1 | 2005 | 751 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 3438 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 739 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1038 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 2488 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 1081 | 0.010 |
Why?
|
| United States | 1 | 2017 | 15433 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2002 | 429 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 1013 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 620 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1538 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 3472 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 1529 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 1534 | 0.010 |
Why?
|
| Kidney | 1 | 2006 | 2146 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 7702 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 2809 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 6942 | 0.010 |
Why?
|
| Markov Chains | 1 | 1994 | 175 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 362 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1994 | 587 | 0.010 |
Why?
|
| Brain | 1 | 2006 | 4113 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 6869 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1991 | 139 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 418 | 0.010 |
Why?
|
| Cricetinae | 1 | 1991 | 706 | 0.010 |
Why?
|